Trials / Terminated
TerminatedNCT02247479
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 906 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lampalizumab | Participants will receive 10 mg dose of lampalizumab administered intravitreally. |
| OTHER | Sham | A sham injection is a procedure that mimics an intravitreal injection of lampalizumab. |
Timeline
- Start date
- 2014-09-18
- Primary completion
- 2018-01-29
- Completion
- 2018-01-29
- First posted
- 2014-09-25
- Last updated
- 2019-06-26
- Results posted
- 2019-04-23
Locations
145 sites across 19 countries: United States, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Peru, Poland, Slovakia, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02247479. Inclusion in this directory is not an endorsement.